Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Feb 1:11:610904.
doi: 10.3389/fendo.2020.610904. eCollection 2020.

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients

Francesca Delle Cese  1 , Andrea Corsello  1 , Marco Cintoni  2 , Pietro Locantore  1 , Alfredo Pontecorvi  1 , Salvatore Maria Corsello  1 , Rosa Maria Paragliola  1
Affiliations
Observational Study

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients

Francesca Delle Cese et al. Front Endocrinol (Lausanne). .

Abstract

Objective: The use of once-daily dual-release HC (DR-HC) in primary adrenal insufficiency (PAI) is often associated with benefits in metabolic parameters when compared to immediate-release HC (IR-HC). In this study, we evaluated the effects on clinical, biochemical and metabolic parameters of switching from IR-HC to lower-dose DR-HC given both in once and fractionated daily doses.

Methods: Twenty autoimmune-PAI subjects were included. Patients on 30 mg/day divided in three doses IR-HC regimen (group A) were switched to DR-HC 25 mg/day given in two daily doses (20 mg in the morning and 5 mg at 2.00 p.m.); patients on 25 mg/day divided in two doses IR-HC regimen (group B) were switched to DR-HC 20 mg once daily. Biochemical and metabolic parameters, BMI and quality of life (QoL) were evaluated at the baseline and six months after the switch.

Results: Our small non-randomized study with short follow up showed significant benefits in both group A and group B without any apparent side-effects. After the switch to DR-HC, a significant decrease in adrenocorticotropic hormone (ACTH), HbA1c, total cholesterol, triglycerides, LDL, cholesterol, BMI as well as a significant improvement in QoL, were observed in both groups. At 6 months, ACTH levels were lower in group A while HbA1C and total cholesterol were lower in group B.

Conclusion: The DR-HC is a valid and effective therapeutic strategy to improve the metabolic control and the QoL in PAI. The reduction of ACTH levels with DR-HC regimens reflects a better biochemical control of PAI, obtained by using a lower dose and more physiological HC formulation. Both once-daily and fractionated daily doses of DR-HC showed advantages compared with IR-HC formulation.

Keywords: adrenocorticotropic hormone; dual-release hydrocortisone; immediate-release hydrocortisone; modified-release hydrocortisone; primary adrenal insufficiency.

PubMed Disclaimer

Conflict of interest statement

FDC, RMP, PL, and SMC are investigators for the EU-AIR study, which is sponsored by Shire. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The figure reports the study design. The study is a prospective, two-armed, interventional study with a 6 months observational period. Biochemical and metabolic parameters and AddiQoL-30 test have been collected at baseline and six months after the switch to DR-HC in group A and group B. ACTH, adrenocorticotropic hormone; BID, divided in two doses; BMI, body mass index; DR-HC, dual-release hydrocortisone; HbA1c, glycated hemoglobin; IR-HC, immediate-release hydrocortisone; QoL, quality of life; TID, divided in three doses.
See this image and copyright information in PMC

References

    1. Erichsen MM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab (2009) 94(12):4882–90. 10.1210/jc.2009-1368 - DOI - PubMed
    1. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab (2007) 92(10):3912–22. 10.1210/jc.2007-0685 - DOI - PubMed
    1. Johannsson G, Falorni A, Skrtic S, Lennernas H, Quinkler M, Monson JP, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) (2015) 82(1):2–11. 10.1111/cen.12603 - DOI - PubMed
    1. Stewart PM. Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice? J Endocr Soc (2019) 3(6):1150–3. 10.1210/js.2019-00046 - DOI - PMC - PubMed
    1. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2016) 101(2):364–89. 10.1210/jc.2015-1710 - DOI - PMC - PubMed

Publication types

LinkOut - more resources